10-Q: Sanara MedTech Inc. Reports Second Quarter 2024 Results, Revenue Up 28%

Sanara MedTech Inc. reports a 28% increase in revenue for the second quarter of 2024, driven by strong sales of soft tissue repair products.

Summary

• Sanara MedTech Inc. reported a 28% increase in net revenue for the second quarter of 2024, reaching $20.2 million, compared to $15.8 million in the same period last year.
• The company's gross profit also saw a significant increase, rising by 34% to $18.2 million for the quarter.
• The growth was primarily driven by increased sales of soft tissue repair products, including CellerateRX Surgical.
• Operating expenses increased to $21.0 million, up from $15.4 million in the prior year, due to higher sales and marketing costs, executive separation costs and acquisition costs.
• The company reported a net loss of $3.5 million for the quarter, compared to a net loss of $1.9 million in the second quarter of 2023.
• For the six months ended June 30, 2024, net revenue was $38.7 million, a 24% increase from $31.3 million in the same period last year.
• The company's gross profit for the first six months of 2024 was $34.8 million, a 29% increase from $27.0 million in the same period last year.
• The net loss for the first six months of 2024 was $5.3 million, compared to a net loss of $3.1 million for the same period in 2023.
• The company has changed its reportable segments to Sanara Surgical and Tissue Health Plus (THP) to reflect the growing importance of the value-based wound care program.
• The company expects to commercially launch the THP program during the second half of 2025.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While revenue growth is strong and gross margins are high, the increasing net loss and reliance on a single product are concerning. The company's strategic shift towards value-based care is promising, but it is still in the early stages. The sentiment is neutral to slightly negative due to the increased losses.

Positives

• The company experienced a significant increase in revenue and gross profit, driven by strong sales of soft tissue repair products.
• The company has successfully eliminated royalties paid on the sales of CellerateRX Surgical due to the Applied Asset Purchase, improving gross margins.
• The company has secured a $55 million term loan to support growth and acquisitions.
• The company is developing a value-based wound care program through its THP segment, which is expected to provide future growth opportunities.

Negatives

• The company's net loss increased in both the second quarter and the first six months of 2024 compared to the same periods in 2023.
• Operating expenses increased significantly due to higher sales and marketing costs, executive separation costs and acquisition costs.
• The company is still in the development phase for its THP program, which is not expected to generate revenue until the second half of 2025.
• The company has incurred significant interest expense related to its new term loan.

Risks

• The company's future success depends on the successful commercialization of its THP program.
• The company's ability to meet its financial covenants under the CRG Term Loan Agreement is dependent on achieving revenue targets.
• The company's operating expenses are expected to increase significantly in the second half of 2024 due to investments in THP.
• The company faces intense competition in the markets in which it operates.
• The company's ability to maintain and grow clinical acceptance of its products is critical to its success.

Future Outlook

The company expects to commercially launch the THP program during the second half of 2025 and anticipates that THP's operating expenses and net loss will increase by approximately $4.0 to $5.0 million during the six-month period ending December 31, 2024 compared to the six-month period ended June 30, 2024. The company believes its cash on hand, combined with expected cash flows from operations and available proceeds from the CRG Term Loan, will be sufficient to fund its growth strategy and meet its anticipated operating expenses and capital expenditures for at least the next twelve months.

Management Comments

• The company is focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures.
• The company strives to be one of the most innovative and comprehensive providers of effective surgical, wound and skincare solutions.
• The company is continually seeking to expand its offerings for patients requiring treatments across the entire continuum of care in the United States.

Industry Context

The company operates in the medical technology sector, specifically focusing on surgical, chronic wound, and skincare markets. The company's strategy to expand its offerings across the continuum of care aligns with the industry trend of providing comprehensive solutions. The company's focus on value-based care through its THP segment is also in line with the industry's shift towards cost-effective and outcome-driven healthcare solutions.

Comparison to Industry Standards

• Sanara's revenue growth of 28% in Q2 2024 is strong compared to the average growth rate of medical device companies, which typically ranges from 5% to 15%.
• The company's gross margin of approximately 90% in Q2 2024 is above the industry average for medical device companies, which typically ranges from 60% to 80%.
• The company's net loss is a concern, but it is not uncommon for growth-stage medical device companies to operate at a loss while investing in R&D and market expansion.
• The company's focus on value-based care through its THP segment is a differentiating factor compared to many traditional medical device companies.
• The company's reliance on a single product, CellerateRX Surgical, for a significant portion of its revenue is a risk, but the company is actively diversifying its product portfolio through acquisitions and internal development.
• Compared to companies like Smith+Nephew and Integra LifeSciences, Sanara is smaller and more focused on specific niches within the wound care market. However, Sanara's growth rate is higher than these larger, more established players.

Management Changes

Corporate Governance

Related Party Transactions

• The company has an exclusive sublicense agreement with CGI Cellerate RX, LLC, an affiliate of The Catalyst Group, Inc., for the distribution of CellerateRX Surgical products.
• The company has license agreements with Rochal Industries, LLC, a related party, for various antimicrobial products.
• The company has a consulting agreement with Ann Beal Salamone, a director of the company and a significant shareholder of Rochal Industries, LLC.
• The company has a Transaction Advisory Services Agreement with Catalyst, a related party.

Stakeholder Impact

• Shareholders may be concerned about the increasing net loss, but the company's revenue growth and strategic initiatives are positive.
• Employees may benefit from the new incentive plan and the company's growth prospects.
• Customers may benefit from the company's expanded product offerings and value-based care programs.
• Suppliers may benefit from the company's increased sales and production volumes.
• Creditors may be concerned about the company's increasing debt levels, but the company's revenue growth and strategic initiatives are positive.

Next Steps

• The company plans to continue expanding its independent distribution network.
• The company plans to further develop its THP program and commercially launch it in the second half of 2025.
• The company plans to make another borrowing under the CRG Term Loan during the second half of 2024.
• The company plans to continue to develop its product pipeline.

Key Dates

Keywords

Sanara MedTech, CellerateRX Surgical, Tissue Health Plus, wound care, medical technology, revenue growth, net loss, operating expenses, term loan, acquisitions, soft tissue repair, bone fusion